Today Viz.ai, an artificial intelligence care coordination company, shared the closing of its Series C funding round worth $71 million.

Scale Venture Partners and Insight Partners led the financing with participation from Greenoaks, Kleiner Perkins, Threshold Ventures, CRV, Innovation Endeavors and Susa Ventures.

This latest round comes about a year and a half after its $50 million Series B raise. To date, Viz.ai has raised $150 million.

WHAT IT DOES

The Viz.ai platform harnesses AI to automatically review CT scans and search for suspected large vessel occlusions, a common type of stroke. Once identified, the platform alerts all members of the stroke team to triage the patient.

In clinical studies, the Viz LVO system could identify and notify care teams of suspected strokes in under six minutes, allowing for faster treatment and better patient outcomes, Viz.ai said.

The company also has tools for sharing patient information before the CT scan takes place, offering patient referrals, viewing scans on mobile devices, as well as a HIPAA-compliant communication platform for clinical care coordination.

WHAT ITS FOR

With this raise, Viz.ai plans to broaden its AI care coordination tool to support other areas of acute care, such as cardiology, pulmonary and trauma. It also aims to grow into new global markets.

“This latest round of funding validates the potential of Viz.ai’s technology, both in and beyond stroke care coordination,” Chris Mansi, cofounder and CEO of Viz.ai, said in a statement.

“The investment will allow us to expedite our effort to bring the power of artificial intelligence and advanced mobile technology to prevent care breakdowns, improve patient outcomes and experience, and improve economics across the entire health system, both in the United States and Europe.”

MARKET SNAPSHOT

The company’s stroke-detecting clinical decision-support tool received de novo 510(k) clearance in 2018, and since then the company has worked to expand its reach through new workflows and partnerships. Viz.ai teamed up with Medtronic in 2019 to speed up the adoption of the Viz LVO platform into more stroke-treatment centers in the U.S.

The AI stroke software also landed a New Technology Add-on Payment (NTAP) designation from the Centers for Medicare and Medicaid Services last year, which gives it an add-on payment of $1,040 per use in treating a patient with a stroke or suspected stroke.

AI clinical decision-support technologies have taken off over the last year, in part due to the pandemic.

Also in the stroke imaging space is RapidAI, which recently received clearance from the FDA for its Rapid ASPECTS neuroimaging analysis device.

Outside of strokes, this kind of tech is being used to monitor patient risks in intensive care units, to support cancer diagnostics and to predict COVID-19 complications.